Blog
RSS FeedPosted by Michael Wonder on 20 Dec 2015
Recommendations made by the PBAC - November 2015
18 December 2015 - The recommendations from the November 2015 PBAC meeting are now available. ...
Posted by Michael Wonder on 19 Dec 2015
Meeting highlights from the CHMP meeting - 14-17 December 2015
18 December 2015 - The European Medicines Agency’s CHMP recommended nine new medicines for marketing authorisation at its December 2015 meeting. ...
Posted by Michael Wonder on 19 Dec 2015
EMA fast-tracks new oral treatment for non-small cell lung cancer
18 December 2015 - The EMA has recommended granting a conditional marketing authorisation for Tagrisso (osimertinib) for the treatment of adults ...
Posted by Michael Wonder on 17 Dec 2015
FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes
16 December 2015 - The U.S. FDA today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic ...
Posted by Michael Wonder on 16 Dec 2015
CADTH calls for feedback: anti–vascular endothelial growth factor drugs for retinal conditions
16 December 2015 - A draft recommendation on the anti–vascular endothelial growth factor drugs for retinal conditions is now available for ...
Posted by Michael Wonder on 16 Dec 2015
NICE recommends elosulfase alfa (Vimizim) for treatment of very rare life-limiting genetic disorder under managed access agreement
16 December 2015 - In final guidance as part of its Highly Specialised Technologies Programme, NICE has recommended Elosulfase alfa (Vimizin, ...
Posted by Michael Wonder on 16 Dec 2015
NICE issues guidance not recommending apremilast for psoriatic arthritis
16 December 2015 - NICE has published final guidance today which does not recommend apremilast (Otezla, Celgene) for adults with active ...
Posted by Michael Wonder on 16 Dec 2015
Kadcyla price too high for routine NHS funding, says NICE in final guidance
16 December 2015 - NICE has issued its final guidance on the use of Kadcyla (trastuzumab emtansine) as a treatment for ...
Posted by Michael Wonder on 16 Dec 2015
NICE says yes to dry eye disease treatment in final guidance
16 December 2015 - NICE has published final guidance recommending cyclosporin (Ikervis, Santen Pharmaceutical) for treating severe keratitis in adults with ...
Posted by Michael Wonder on 15 Dec 2015
FDA approves Bridion to reverse effects of neuromuscular blocking drugs used during surgery
15 December 2015 - The U.S. FDA today approved Bridion (sugammadex sodium) injection to reverse the effects of neuromuscular blockade induced ...
Posted by Michael Wonder on 15 Dec 2015
Evolocumab: no evidence of additional clinical benefits says IQWiG
15 December 2015 - The dossier did not contain appropriate data for patients with hypercholesterolaemia nor for mixed dyslipidaemia. ...
Posted by Michael Wonder on 15 Dec 2015
Canada's ERC recommends the funding of Revlimid (lenalidomide) for patients with newly diagnosed multiple myeloma
3 December 2015 - The recommendation is for the use of lenalidomide in combination with low-dose dexamethasone for treatment of ...
Posted by Michael Wonder on 14 Dec 2015
NICE intends to recommend olaparib for ovarian, fallopian tube and peritoneal cancer after company provides more information
11 December 2015 - The draft recommendations say that olaparib should be available for people only if they have had ...
Posted by Michael Wonder on 14 Dec 2015
Canada's ERC recommends panitumumab (Vectibix) for use by patients with metastatic RAS colorectal cancer
3 December 2015 - The ERC has recommended the use of panitumumab in combination with FOLFOX for the first-line treatment of ...
Posted by Michael Wonder on 13 Dec 2015
Mesalazine (Asacol) 800 mg tablets approved in NZ
11 December 2015 - PHARMAC is pleased to announce the approval of an agreement with Baxter Healthcare Limited to fund Asacol ...